Clinical Trials Logo

Clinical Trial Summary

Acute septic arthritis is a rare but life-threatening and functionally serious disease. The improvement or disappearance of pain and functional recovery are sometimes difficult to obtain, with in some cases the persistence of synovitis due to a prolonged local inflammatory response, despite early and effective treatment. The consequences are significant for patients with often significant chronic pain, repercussions on autonomy and/or profession. An unfavorable evolution with joint destruction and need for replacement by a prosthesis is not uncommon. Corticosteroid therapy is widely used in rheumatology in similar tables, for the purpose of drug synovectomy, with good results. The risk of infection remains the main contraindication to its use. There are very few studies on its use in septic arthritis, either fundamentally or in humans, for which there are no data in adults. However, these have shown results encouraging the investigators not to neglect this therapy.


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT05531227
Study type Observational
Source University Hospital, Strasbourg, France
Contact Jeannot GAUDIAS, MD
Phone 33 3 68 76 50 64
Email jeannot.gaudias@chru-strasbourg.fr
Status Recruiting
Phase
Start date June 20, 2022
Completion date December 13, 2023

See also
  Status Clinical Trial Phase
Completed NCT04460144 - Rapid Diagnostic Test for Septic Arthritis
Completed NCT03615781 - Two Versus Four Weeks of Antibiotic Treatment in Native Joint Arthritis N/A